Man Charged With Posing as Doctors to Obtain Ozempic and Mounjaro Prescriptions Across 19 States
An Illinois man pleaded not guilty on Monday to a four-count federal indictment charging him with wire fraud, healthcare fraud, and aggravated identity theft. Prosecutors allege he impersonated physicians across roughly 19 states to obtain unauthorized prescriptions for GLP-1 medications, including Ozempic and Mounjaro. The charges, brought by the US Attorney's Office for the Southern District of New York, stem from a scheme prosecutors say began in early 2023 and continued through March 2026.
Rodney Greer was arrested in Chicago in June following a federal criminal complaint. According to court filings and a US Justice Department news release, Greer allegedly called approximately 261 pharmacies on about 3,329 occasions between January 2023 and March 2026, using doctors' identifying information to impersonate them. Prosecutors said he obtained physicians' names and national provider identification numbers (NPI), maintaining handwritten lists with the personal information of approximately 60 doctors across 19 states. Greer allegedly claimed to be a healthcare provider, falsely identified himself as a physician, and provided other false information to receive GLP-1 and other prescription medications. The Guardian
GLP-1 medications are a class of drugs originally developed for type 2 diabetes that help regulate blood sugar and, as a secondary effect, reduce appetite. In recent years, their use for weight loss has driven demand far beyond what manufacturers can supply.
Federal prosecutors in Manhattan contended that customers paid Greer money in exchange for obtaining illicit prescriptions. Greer allegedly operated under the online alias "$hotboy1" and also went by the name Christian Marchand. A payment app account under the username $hotboy1 listed two display names: "Christian Marchand" and "Rod Greer." The criminal complaint included an exchange where Greer's name appeared as "$hotboy1 Christian Marchand." The Guardian
The complaint details transaction records from payment apps that allegedly link Greer to the prescription scheme. One payment app account received seven payments from a supposed patient, with one transaction stating "I'm ready for my order." Another payment description mentioned a patient's name followed by "OZE," the first three letters of Ozempic. A separate payment description stated "deposit for next pen." The Guardian
Communications preserved in court filings show Greer interacting with at least one buyer of Ozempic. In late March 2023, the buyer messaged: "[w]hat good playa … U forgot bout ya boy." Greer allegedly responded: "[N]ope it's a process, should know something today." In June 2023, Greer allegedly sent a message stating: "[s]o go ahead with the 2mg?" The buyer then asked: "[d]id you put in my thing for this week my shjt [sic] is done," to which Greer allegedly replied "[y]es sir." That buyer has since pleaded guilty under a cooperation agreement related to Greer's alleged scheme. The Guardian
A cooperation agreement is a deal in which a defendant pleads guilty and agrees to assist prosecutors, often by providing testimony or evidence, in exchange for a potentially reduced sentence.
Prosecutors said Greer enabled the "unauthorized redemption" of hundreds of thousands of dollars in health insurance plan benefits for his clients. He caused fraudulent claims for medications lacking any valid prescription to be submitted to Medicaid, the government health insurance program for low-income Americans, and private insurance providers, according to a criminal complaint filed earlier this year. Justice Department
Greer pleaded not guilty to the four-count indictment, which was unsealed following his arrest. The indictment charges wire fraud, healthcare fraud, and aggravated identity theft. Greer's attorney did not immediately respond to a request for comment.
The broader context here involves a vulnerability in the pharmaceutical supply chain that extends beyond individual fraud. NPI numbers are publicly searchable identifiers assigned to healthcare providers by the Centers for Medicare and Medicaid Services, designed for billing and credentialing purposes. Their availability, combined with the volume of calls a single individual allegedly made to pharmacies across multiple states, raises questions about the verification protocols that pharmacies and insurers apply when prescriptions are called in under a provider's name. Greer allegedly contacted 261 pharmacies over three years, yet the scheme persisted until 2026 before federal intervention.
The case also lands amid intense demand for GLP-1 medications. Ozempic (semaglutide) and Mounjaro (tirzepatide) have faced recurring supply constraints as demand outpaced manufacturing capacity. That scarcity created a secondary market in which buyers sought prescriptions through unconventional channels. The payment descriptions cited in the complaint, with shorthand references to "OZE" and "next pen," suggest a transactional economy built around continued access to injectable GLP-1 medications outside the standard prescriber-patient relationship.
The cooperation agreement with the buyer who communicated with Greer indicates that prosecutors are building their case with insider testimony, not just transactional records. This is a standard prosecutorial approach in healthcare fraud cases, where conspirators who plead guilty and cooperate can provide context for wire transfers and pharmacy call records that might otherwise appear ambiguous. The transition from a criminal complaint to a four-count indictment in the Southern District of New York signals that a grand jury found sufficient evidence to formally charge Greer on all counts.
